Hohenlinden, Germany

Max Bichlmaier



 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Max Bichlmaier: Innovator in Radioactive Substance Application

Introduction

Max Bichlmaier is a notable inventor based in Hohenlinden, Germany. He has made significant contributions to the field of medical technology, particularly in the application of radioactive substances for therapeutic purposes. His innovative approach has the potential to enhance treatment methods in oncology.

Latest Patents

Max Bichlmaier holds a patent for an "Applicator for applying a radioactive substance to a biological tissue." This invention includes a container for receiving the radioactive substance, an application device that connects to the container, and a conveying device that supplies the radioactive substance from the container into the application device. This design aims to improve the precision and effectiveness of applying radioactive treatments to biological tissues.

Career Highlights

Max Bichlmaier is currently associated with Oncobeta International GmbH, a company focused on advancing cancer treatment technologies. His work at Oncobeta has positioned him as a key player in the development of innovative medical devices that utilize radioactive substances for therapeutic applications.

Collaborations

Max collaborates with talented professionals in his field, including Cesidio Cipriani and Maria Desantis. Their combined expertise contributes to the advancement of medical technologies and the development of effective treatment solutions.

Conclusion

Max Bichlmaier's contributions to the field of medical technology, particularly through his innovative patent, demonstrate his commitment to improving cancer treatment methods. His work continues to inspire advancements in the application of radioactive substances in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…